US 12,435,151 B2
Anti-TNFR2 antibodies and uses thereof
Yu Zhou, San Francisco, CA (US); James D. Marks, Kensington, CA (US); Marco Muda, New Haven, CT (US); James Frank Sampson, Medford, MA (US); Eric M. Tam, Cooperstown, NY (US); and Ross Bane Fulton, Southborough, MA (US)
Assigned to Merrimack Pharmaceuticals, Inc., Massachusetts (MA)
Appl. No. 17/434,340
Filed by Merrimack Pharmaceuticals, Inc., Cambridge, MA (US); and The Regents of the University of California, Oakland, CA (US)
PCT Filed Feb. 28, 2020, PCT No. PCT/US2020/020456
§ 371(c)(1), (2) Date Aug. 26, 2021,
PCT Pub. No. WO2020/180712, PCT Pub. Date Sep. 10, 2020.
Claims priority of provisional application 62/902,164, filed on Sep. 18, 2019.
Claims priority of provisional application 62/812,875, filed on Mar. 1, 2019.
Prior Publication US 2022/0281990 A1, Sep. 8, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 47/42 (2017.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 47/42 (2013.01); A61P 35/00 (2018.01); A61P 37/00 (2018.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/732 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01)] 16 Claims
 
1. An isolated antibody which binds to human TNFR2 comprising heavy and light chain CDRs of the heavy and light chain variable region pairs of SEQ ID NOs: 117 and 118, respectively.